Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botox for Hidradenitis Suppurativa: Within-Person Randomized Double-Blind Controlled Study
2024-519946-54-00Phase 4Authorised
- Sponsor
- Gentofte Hospital
- Start
- Feb 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of botulinum toxin type A in hidradenitis suppurativa (HS) (2 arms), sponsored by Gentofte Hospital. Primary endpoint: Reduction in IHS4 score. Planned start Feb 2025; status: authorised.
02
Drugs
botulinum toxin type A
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2024-519946-54-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519946-54-00.